Immunovant/$IMVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunovant
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Ticker
$IMVT
Sector
Primary listing
Employees
362
Headquarters
Website
Immunovant Metrics
BasicAdvanced
$3.3B
-
-$2.84
0.66
-
Price and volume
Market cap
$3.3B
Beta
0.66
52-week high
$30.63
52-week low
$12.72
Average daily volume
1.7M
Financial strength
Current ratio
12.321
Quick ratio
11.358
Profitability
EBITDA (TTM)
-470.691
Effective tax rate (TTM)
-0.39%
Management effectiveness
Return on assets (TTM)
-47.07%
Return on equity (TTM)
-77.58%
Valuation
Price to book
5.32
Price to tangible book (TTM)
5.32
Price to free cash flow (TTM)
-7.155
Free cash flow yield (TTM)
-13.98%
Free cash flow per share (TTM)
-2.647
Growth
Earnings per share change (TTM)
47.71%
3-year earnings per share growth (CAGR)
24.83%
What the Analysts think about Immunovant
Analyst ratings (Buy, Hold, Sell) for Immunovant stock.
Bulls say / Bears say
Robust cash runway—As of June 30, 2025, Immunovant held around $598.9 million in cash and equivalents, enough to fund announced clinical programs until the expected Graves’ disease readout in 2027.
Positive clinical proof points—Recent batoclimab studies achieved their primary endpoint in myasthenia gravis (showing MG-ADL improvements of 5.6 and 4.7 points at week 12), and delivered an 84% responder rate in CIDP for IgG reductions above 70%, validating the FcRn inhibition strategy and supporting registrational trials for IMVT-1402.
Strengthened balance sheet—A successful $450 million private placement at $20 per share in January 2025 added meaningful, non-dilutive capital for advancing the pipeline and maintaining operational flexibility.
High cash burn and mounting losses—Immunovant reported a fiscal 2025 net loss of $413.8 million and first quarter R&D expenses of $101.2 million, highlighting a rapid burn rate that could require additional equity dilution.
Strategic narrowing of lead asset—Leadership changes in April 2025 were accompanied by cutting IMVT-1402 target indications from ten to six, raising questions about execution and potentially shrinking future market opportunities.
Lost near-term commercialization path—Despite successful Phase 3 results with batoclimab in myasthenia gravis and CIDP, Immunovant will not pursue approval, passing up immediate revenue and shifting full commercial hopes to the still-experimental IMVT-1402.
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Immunovant Financial Performance
Revenues and expenses
Immunovant Earnings Performance
Company profitability
Immunovant News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunovant stock?
Immunovant (IMVT) has a market cap of $3.3B as of October 26, 2025.
What is the P/E ratio for Immunovant stock?
The price to earnings (P/E) ratio for Immunovant (IMVT) stock is 0 as of October 26, 2025.
Does Immunovant stock pay dividends?
No, Immunovant (IMVT) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Immunovant dividend payment date?
Immunovant (IMVT) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunovant?
Immunovant (IMVT) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.